Search research articles
Contact Us
Filters
Showing results (321-330 of 324) with videos related to
Page
of 33
Sort By:
You have reached the last page of results.
This site can display upto 324 results.
Proceedings of the National Academy of Sciences of the United States of America
|
April 29, 2026
Quantitative assessment of flow between cerebrospinal and interstitial fluid compartments in humans
Anders Wåhlin, Sofia Behndig, Johan Eriksson De Ryst, et al.
Allergy
|
September 13, 2019
Pollen exposure weakens innate defense against respiratory viruses
Stefanie Gilles, Cornelia Blume, Maria Wimmer, et al.
Genome Medicine
|
December 13, 2022
Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
Bożena Bruhn-Olszewska, Hanna Davies, Daniil Sarkisyan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2006
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist
Kimberly E Vanover, David M Weiner, Malath Makhay, et al.
Page
of 33
Search research articles
Search
Showing results (321-330 of 324) with videos related to
Sort By:
Page
of 33
You have reached the last page of results.
This site can display upto 324 results.
Proceedings of the National Academy of Sciences of the United States of America
|
April 29, 2026
Quantitative assessment of flow between cerebrospinal and interstitial fluid compartments in humans
Anders Wåhlin, Sofia Behndig, Johan Eriksson De Ryst, et al.
Allergy
|
September 13, 2019
Pollen exposure weakens innate defense against respiratory viruses
Stefanie Gilles, Cornelia Blume, Maria Wimmer, et al.
Genome Medicine
|
December 13, 2022
Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
Bożena Bruhn-Olszewska, Hanna Davies, Daniil Sarkisyan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2006
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist
Kimberly E Vanover, David M Weiner, Malath Makhay, et al.
Page
of 33